A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy
NCT06351904 · Phase 1 · St Leonards, New South Wales, Australia
- Condition
- Bladder Cancer
- Disease stage
- Stage I-IV
- Phase
- Phase 1
- Study type
- DRUG
- Intervention
- RAG-01
- Age
- 18 Years to 75 Years
- Gender
- All
- Sponsor
- Ractigen Therapeutics.
- Research institution
- Ractigen Therapeutics.
- Facility
- GenesisCare North Shore
- Research center
- GenesisCare North Shore
Summary
This is an open label, multi-center study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of RAG-01 in patients with NMIBC who have failed BCG therapy.
Detailed description
This study includes a dose escalation and a dose expansion. The dose escalation part will adopt a '3+3' dose escalation design. Additional subjects may be enrolled to have approximately 12 patients in each selected dose level for RDE determination. A randomized, open label, parallel-arm study will be conducted during the dose expansion part for further dose exploration. Approximately 40-60 subjects will be randomized in a 1:1 ratio into two treatment groups with dose levels selected from dose escalation part of the study. Randomization will be stratified based on disease type at enrollment (papillary-only vs. CIS). A dose selection analysis will be performed to assess safety, efficacy, PK, and PD, where applicable, to determine the optimal dose for RAG-01. The main study period includes the screening, initial treatment and DLT assessment period, second and third treatment period and the sequential follow-up period.
Inclusion criteria
1. Ability to understand the study and have signed the informed consent form; 2. Any adult ≥ 18 years old; 3. Pathologically confirmed high grade NMIBC defined as grade 2 or grade 3 disease; 4. Expected survival ≥ 6 months; 5. ECOG PS ≤2; 6. Sufficient organ functions, as defined below: Investigations Hematology Absolute Neutrophil Count (ANC): ≥ 1.5 x 109/L Hemoglobin: ≥ 90 g/L Platelet: ≥ 100 x 109/L Liver Function Serum bilirubin: ≤ 1.25×ULN or 2.5×ULN（with Gilbert syndrome） AST \& ALT: ≤ 2.5×ULN Renal Function Creatinine Clearance (Cockcroft-Gault equation): ≥ 30 mL/min 7. Subject must be able to tolerate catheterization; 8. Female subject of childbearing potential and her spouse must use adopt effective contraception (non-pharmacological contraception required) from signing informed consent to within 6 months after the last instillation;
Exclusion criteria
1. Subject who is allergy to RAG-01 or similar products; 2. Except for TURBT, the subject received other anti-tumor treatments, and the last administration date is within ≤ 21 days or 5 half-lifes whichever is shorter from the date of signing ICF; 3. Subject with imaging examination diagnosed extravesical metastasis, including ureter and urethra; 4. Subject has other malignancies within the past 3 years, except for adequately treated carcinoma of the cervix, basal or squamous cell carcinomas of the skin, or adenocarcinoma of the prostate that has been surgically treated with a post-treatment PSA that is non-detectable; 5. The following illnesses have not been relieved to CTCAE 0-1: 1. Uncontrolled acute and chronic infections, such as pneumonia, biliary tract infection, hepatitis B virus infection and hepatitis C virus infection; 2. Dyspnea; 3. Acute and chronic kidney injury, and inflammation; 4. Urinary incontinence; 5. Urinary frequency; 6. Urinary tract obstruction (except benign prostatic hypertrophy); 6. Subject could not hold the urine for at least 90 mins due to any reason; 7. New York Heart Association (NYHA) 3 or 4 grade; 8. Coronary heart disease related symptoms have not been relieved to CTCAE 0-1, including: myocardial infarction, unstable angina pectoris, congestive heart failure and arrhythmia; 9. Subject with QTc \>470 msec. 10. Cerebrovascular accidents have not been relieved to CTCAE 0-1; 11. HIV positive; Active hepatitis B or C. For active HBV, it's defined as HBsAg positive with HBV DNA ≥ ULN, for active HCV, it's defined as HCV antibody positive with HCV RNA ≥ ULN, respectively. 12. Subject is pregnant or lactating during the treatment period; 13. History of central nervous system or psychiatric disorders, e.g., epilepsy or dementia; 14. Other severe systemic diseases which might compromise the subject's compliance to the study, e.g., uncontrolled diabetes, gastrointestinal disorders, and renal diseases; 15. Any other situations which are judged by the investigator, would exposure the subject to unnecessary risk, therefore he/she is not eligible.
Primary outcomes
Safety and tolerability of RAG-01 in patients with non-muscle-invasive bladder cancer (NMIBC); Maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of RAG-01